Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF.

Xue-wen Yang; Li-min MA; Xiao-qiang Zhao; Lin-hai Ruan

Return

Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF.

Author: Xue-Wen YANG ¹ ; Li-Min MA ¹ ; Xiao-Qiang ZHAO ¹ ; Lin-Hai RUAN ²
Author Information

1. The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.
2. The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, Henan Province, China. E-mail: 13783131306@163.com.
Publication Type:Journal Article
MeSH: Acute Disease; Antineoplastic Agents; administration & dosage; therapeutic use; Drug Therapy, Combination; Fibroblast Growth Factor 2; metabolism; Humans; Leukemia, Myeloid, Acute; drug therapy; Thalidomide; administration & dosage; analogs & derivatives; therapeutic use; Vascular Endothelial Growth Factor A; metabolism
From: Journal of Experimental Hematology 2016;24(3):702-706
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the clinical efficacy of regimen consisting of lenalidomide combined with chemotherapy for acute leukemia and its impact on vascular endothilial growth factor (vEGF) and basic fibroblast growth factor (bFGF), and to analyze the relationship lenalidomide with therapeutic efficacy of leukemia.
METHODSThe patients with newly diagnosed acute myeloid leukemia (except M3) from October 2013 to October 2014 in our hospital were randomly divided into 2 groups: chemotherapy+placebo (CP) group and lenalidomide+chemotherapy (LC) group. In addition, healthy persons were used as healthy controls (HC). The expression of VEGF and bFGF was detected by ELISA, and the therapeutic efficacy for AML patients was analyzed.
RESULTSThe therapeutic efficacy in LC group and CP group was 87.9% and 77.2% respectively. Before treatment, the VEGF level in LC and CP groups was obviously higher than that in HC group; after treatment, the VEGF level significanthy decreased, and the decreased degree in LC group was larger than that in CP group. Before treatment, the bFGF level in LC and CP groups was higher than that in HC group; after treatment, the bFGF level decreased, and decreased degree in LC group was larger than that in CP group.
CONCLUSIONThe lenalidomide combined with chemotherapy can significantly decrease the expression level of VEGF and bFGF, and enhance the remission rate of patients with AML.